Turkish Journal of Medical Sciences
Volume 50

Number 4

Article 60

1-1-2020

Ocular toxicity of intravitreal golimumab in a rabbit model
CEREN DURMAZ ENGİN
SERAP CİLAKER MIÇILI
OSMAN YILMAZ
HÜSNÜ ALPER BAĞRIYANIK
BEKİR UĞUR ERGÜR

See next page for additional authors

Follow this and additional works at: https://journals.tubitak.gov.tr/medical
Part of the Medical Sciences Commons

Recommended Citation
ENGİN, CEREN DURMAZ; MIÇILI, SERAP CİLAKER; YILMAZ, OSMAN; BAĞRIYANIK, HÜSNÜ ALPER;
ERGÜR, BEKİR UĞUR; ÖNEN, FATOŞ; and SAATCİ, ALİ OSMAN (2020) "Ocular toxicity of intravitreal
golimumab in a rabbit model," Turkish Journal of Medical Sciences: Vol. 50: No. 4, Article 60.
https://doi.org/10.3906/sag-1911-11
Available at: https://journals.tubitak.gov.tr/medical/vol50/iss4/60

This Article is brought to you for free and open access by TÜBİTAK Academic Journals. It has been accepted for
inclusion in Turkish Journal of Medical Sciences by an authorized editor of TÜBİTAK Academic Journals. For more
information, please contact academic.publications@tubitak.gov.tr.

Ocular toxicity of intravitreal golimumab in a rabbit model
Authors
CEREN DURMAZ ENGİN, SERAP CİLAKER MIÇILI, OSMAN YILMAZ, HÜSNÜ ALPER BAĞRIYANIK, BEKİR
UĞUR ERGÜR, FATOŞ ÖNEN, and ALİ OSMAN SAATCİ

This article is available in Turkish Journal of Medical Sciences: https://journals.tubitak.gov.tr/medical/vol50/iss4/60

Turkish Journal of Medical Sciences

Turk J Med Sci
(2020) 50: 1111-1122
© TÜBİTAK
doi:10.3906/sag-1911-11

http://journals.tubitak.gov.tr/medical/

Research Article
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Background/aim: To investigate the effect of intravitreal golimumab on rabbit retina histopathology.
Materials and methods: Sixteen albino New Zealand rabbits were divided into three groups. The right eye of each rabbit in groups I, II,
and III received a single intravitreal injection of 5 mg/0.05 mL (6 eyes), 10 mg/0.1 mL (6 eyes), or 20 mg/0.2 mL (4 eyes) golimumab,
while left eyes served as controls with the same volume of a balanced salt solution injection. All animals were examined using slit-lamp
biomicroscopy and indirect ophthalmoscopy before and after intravitreal injection and at days 1 and 7. Animals were euthanized on day
7 and the eyes were enucleated for immunohistochemistry evaluation and electron microscopic examination of the retinas.
Results: For groups I, II, and III, the number of cells in the outer nuclear layer and the inner nuclear layer was decreased compared to
those in the control groups. In group I, the percentage of caspase-3 staining of the outer nuclear layer was significantly higher than that
in the control. For groups II and III, TUNEL and caspase-3 staining percentages in the outer and inner nuclear layers were found to be
significantly higher than those for the control groups. In the ganglion cell layer, for groups I, II, and III, neither TUNEL nor caspase-3
staining percentages showed any significant difference between two groups. No significant dose-dependent relationship was found for
increasing doses of golimumab in all layers. Myelin figures and karyorrhexis in the photoreceptor cells were prominent in electron
microscopy of the golimumab-injected eyes.
Conclusion: Golimumab caused apoptosis in both photoreceptors and bipolar cells of the rabbit retina. Potential retinal toxicity of
intravitreal golimumab should be considered if an intravitreal administration is planned.
Key words: Apoptosis, golimumab, intravitreal anti-TNF drugs, retina

1. Introduction
Tumor necrosis factor alpha (TNF-α) is a cytokine
primarily released by macrophages, T lymphocytes, and
fibroblasts. While it stimulates apoptotic cell death and
inflammation, it also inhibits viral replication and tumor
cell growth [1].
In diabetic retinopathy (DRP), increased TNF-α
levels due to oxidative stress induce disorganization of
retinal vascular structures and neovascularization [2].
Higher serum and aqueous TNF-α levels were found in
noninfectious uveitis (NIU) cases compared to those in
healthy controls [3,4]. TNF-α, by means of complement
activation and induction of reactive oxygen species, plays
a major role in the pathogenesis of age-related macular
degeneration (AMD) [5].

TNF-α antagonists were initially used in the treatment
of rheumatoid arthritis (RA) at the end of the 1990s
[6]. Their therapeutic effect on ocular findings of RA,
ankylosing spondylitis (AS), and psoriatic arthritis (PsA)
have been noticed during their systemic administration
[7–9]. However, since TNF-α antagonists increase the
predisposition to infectious diseases and hypersensitivity
reactions, their intravitreal (IVT) use in inflammatory
diseases with only ocular involvement has been considered
[10]. An IVT route is also preferable for using the vitreous
as a drug reservoir and facilitating the drug access to
ocular tissues [11,12]. Thus, etanercept, infliximab, and
adalimumab have been used intravitreally in various
ocular diseases, such as NIU, DRP, exudative AMD, and
postoperative cystoid macular edema [13–16].
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Golimumab is a novel human anti-TNF monoclonal
antibody that can neutralize the human TNF-α molecule
with high affinity and can be used in treatment regimens
with longer intervals, due to its high chemical stability,
longer half-life, and higher potency [17]. Currently,
golimumab is approved for subcutaneous and intravenous
route in moderate–severe RA, active PsA, and active AS
[18]. It is effective against ocular manifestations of AS,
juvenile idiopathic arthritis (JIA), and HLA B-27-positive
arthritis when used systemically [19,20]. Following
subcutaneous injection of golimumab to healthy subjects
or patients the median time to reach maximum serum
concentrations (Tmax) ranged from 2 to 6 days [18].
Safety and efficacy for IVT injections of etanercept,
infliximab, and adalimumab have been studied in animal
models and the treatment of human diseases [10,11,21–
23]. To the best of our knowledge, IVT administration
of golimumab has not yet been reported [24]. The aim of
this study was to investigate the histopathological effects
of IVT golimumab on the retinal layers of rabbit eyes,
by using light microscopy, immunohistochemistry, and
electron microscopy.
2. Materials and methods
2.1. Animals
Animals were treated according to the Association for
Research in Vision and Ophthalmology Statement for the
Use of Animals in Ophthalmic and Vision Research. The
clinical and experimental protocol was approved by the
Animal Care and Use Committee of Dokuz Eylül University
(İzmir, Turkey). Sixteen normal albino New Zealand
rabbits weighing 2–3 kg were divided into three groups.
The original concentration of the drug was preserved in
all groups but the amount of drug injected was changed by
changing the volume. Group I (n = 6), group II (n = 6), and
group III (n = 4) received 5 mg/0.05 mL, 10 mg/0.1 mL,
and 20 mg/0.2 mL golimumab, respectively to the right
eyes, and sham injections of a balanced salt solution (BSS)
of the same volumes were administrated to the left eyes as
controls. According to previous animal studies with antiTNF drugs, if the original concentration was preserved
(not diluted with saline or BSS), then 0.1 mL of these
drugs would contain 2.5 mg etanercept, 1 mg infliximab, 5
or 10 mg adalimumab. Therefore, quantity of proportional
doses in other anti-TNF studies are referenced while
determining the injected doses [22,25,26].
2.2. Procedure
Animals were anesthetized with a mixture of ketamine
hydrochloride (50 mg/kg) and xylazine hydrochloride
(5 mg/kg) along with topical anesthesia (Alcain; Alcon
Laboratories, Inc., Fort Worth, TX, USA). The pupils
were dilated with 2.5% phenylephrine hydrochloride
(Mydfrin; Alcon Laboratories, Inc., Fort Worth, TX,
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USA) and 1% tropicamide (Tropamid; Bilim, İstanbul,
Turkey). After instilling povidone iodine (5%), anterior
chamber paracentesis of an equal volume to the injected
drug was administrated to avoid drug reflux due to
high intraocular pressure. IVT injection of golimumab
(Simponi; Merck Sharp and Dohme, Kenilworth, New
Jersey, USA) was performed approximately 2 mm
posterior to the limbus with a 30-gauge needle attached
to a tuberculin syringe. IOP was checked with TonoPen
Avia (Reichert Technologies, Depew, NJ, USA) after
the procedure and found within normal limits. A 0.3%
ofloxacin eye drop (Exocin; Allergan, Dublin, Ireland) was
administered topically immediately after the injection.
Slit-lamp and funduscopic examinations were performed
pre- and postinjection immediately and repeated at day 7.
The rabbits were kept for 1 week in ambient light on a 12-h
light/12-h dark schedule.
2.3. Clinical observation
To detect clinical signs of toxicity, eyes were carefully
evaluated by slit lamp examination at day 1 and day 7.
Retinal artery patency was checked immediately after the
injection with indirect ophthalmoscopy. At day 7, dilated
fundus examination was repeated to see if there was any
vitreous hemorrhage or retinal detachment.
2.4. Histological examination
At the first postinjection week, rabbits were euthanatized
by intravenous injection of a lethal overdose of ketamin.
The eyes were immediately enucleated and fixed in a 10%
neutral formalin for 24–48 h. Five specimens for each eye
were generated from random areas. For routine histological
procedures, specimens were dehydrated with increasing
alcohol series and then paraffin-perfused. Specimens
were paraffin-embedded, and 5 mm sections were taken
on poly-L-lysin-coated slides using a rotary microtome
(RM 2135; Leica Instruments, Nussloch, Germany) with
disposable metal microtome blades (type N35; Feather
Company, Osaka, Japan). Then tissues stained with
hematoxylin-eosin (H&E). Samples were examined under
a light microscope (Olympus BH2, Japan) and pictures
which showed focal retinal changes of relevant tissue
section were transferred to the computer using a digital
video camera (Olympus DP71, Japan).
2.4.1. Immunohistochemical assessment
After deparaffinization, tissues were dewaxed in xylene
and rehydrated with ethanol. To unmask antigens by the
heat treatment, sections were treated with 10 mM citrate
buffer (Cat No. AP-9003-125 Labvision). After incubated
in a solution of 3% H2O2 to inhibit endogenous peroxidase
activity, sections were incubated with normal serum
blocking solution. They were then incubated in a humid
chamber for 18 h at +4 °C with antibody active-caspase3(Novus), biotinylated IgG, and streptavidin conjugated to
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horseradish peroxidase (Invitrogen-Plus Broad Spectrum
85-9043) in order. Sections were finally incubated with
3,30 diaminobenzidine hydrochloride (DAB) (1718096,
Roche), and nuclei were counterstained with Mayer’s
hematoxylin. Sections were dehydrated through a graded
ethanol series, cleared in xylene, mounted in entellan
(Merck, Germany) and analyzed by a light microscope.
Immunohistochemical evaluation was performed by two
independent experienced histologists, blinded to the
source of the samples taken from five random fields of the
same sections, and the average score was utilized.
2.4.2. Detection of the apoptotic cell death in situ using
the TUNEL method
Apoptosis was investigated by using in situ TUNEL
(TdT-mediated dUTP-digoxigenin Nick End Labeling)
DeadEnd Colorimetric TUNEL system kit (Cat. No:11 684
817 910 Roche, Germany). Tissues were deparaffinized,
rehydrated in alcohol, and microwave-pretreated in
proteinase-K solution at 37 °C for 10 min (Roche, 10
109 819 001). Specimens were washed in phosphatebuffered saline (PBS), incubated with fluorescein labeled
deoxy-UTP and TdT at 37 °C for 60 min and then treated
with converter peroxidase (POD) solution. They were
stained with DAB, counter-stained with hematoxylin and
mounted in entellan. The percentage of TUNEL-positive
cells was determined by counting dye-positive cells from
five random fields.
2.4.3. Electron microscopic examination
Tissue samples were fixed in 2.5% glutaraldehyde.
Specimens were washed and submerged in a solution
containing equal amounts of 2% osmium tetra oxide and
phosphate. Samples were then passed through series of
graded alcohol solutions and afterwards left in propylene
oxide. They were embedded in Araldite-CY 212 and
dodecanyl succinate anhydride (DDSA) for 1 night. The
next day they were placed in gelatin capsules that had been
filled with a combination of Araldite-CY 212, DDSA, and
benzyl dimethylamine (BDMD), and these capsules were
incubated in an autoclave, first for 24 h at 40 °C and then for
48 h at 60 °C. The specimen lumps were cut into semithin
and ultrathin sections with a Leica EM UC. The semithin
sections of 0.5 mm were then stained with toluidine blue
and examined under Olympus BH-2 (Tokyo, Japan) light
microscope. Ultrathin sections of 120 nm were obtained
from selected blocks mounted on copper grids, stained
with uranyl acetate and lead citrate and examined using
a Sigma 300 scanning transmission electron microscopy
(STEM) and images were digitally photographed.
2.5. Statistical analysis
All statistical procedures were performed with SPSS
software for Windows (version 21.0 SPSS, Chicago, IL,
USA). All values were reported as the mean (standard

deviation) or median (range). To compare cell counts
at different retinal layers in H&E staining between
golimumab and BSS groups, Student’s t-test was used.
Immunohistochemical staining differences between
golimumab and BSS groups was compared with Student’s
t-test in normal-distribution groups and Mann–Whitney
U test for nonnormal distribution groups. Statistical
significance was set at 0.05. For comparison of H&E,
TUNEL, and caspase staining percentages of the cells in
different retinal layers in increasing doses and/or volumes,
the Kruskal–Wallis test was used. If a statistically significant
difference was found, paired groups were compared using
the Mann–Whitney U test to find the group that created
the difference. Significance values have been adjusted
using the Bonferroni correction for pairwise comparison
tests.
3. Results
None of the rabbits died during the 1-week study period.
No inflammation or ocular media opacity was observed
with slit lamp microscopy. Retina and optic nerve appeared
normal. No optic atrophy, vitreous hemorrhage, or retinal
detachment was seen in any of the eyes.
3.1. Histopathologic findings
3.1.1. Light microscopy
In H&E staining, decreased cell count was found in both
the outer nuclear layer (ONL) and inner nuclear layer
(INL) in the golimumab-injected eyes compared to the
BSS injected eyes for three different doses. There was
no statistically significant difference in the ganglion cell
layer (GCL). Cell counts at different retinal layers in H&E
staining are shown in Table 1.
There was no significant difference between any of
the study and control groups in terms of ONL, INL, and
GCL cell counts in increasing doses and/or volume (P =
0.054, P = 0.062, and P = 0.370 for the study groups and
P = 0.068, P = 0.072, and P = 0.490 for the control groups
respectively).
3.1.2. Immunohistochemical findings
3.1.2.1. TUNEL staining
The TUNEL staining technique—demonstrating DNA
fragmentation in the apoptotic process—showed that
the TUNEL-positive cell percentage in the INL was
significantly higher in groups I, II, and III compared to
controls. Although the percentage of TUNEL-positive
cells in the ONL was not different from the control in
group I, increased TUNEL positivity in groups II and III
was observed compared to controls. The percentage of
TUNEL-positive cells in the GCL of all study groups was
not significantly different from the control eyes. TUNEL
staining percentages of the cells in different retinal layers
detected in the study are summarized in Table 2.
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Table 1. Cell counts at different retinal layers in H&E staining.
Golimumab

BSS

Mean ± standard
deviation (%)

Mean ± standard
deviation (%)

5 mg/0.05 mL

0.05 mL

Outer nuclear layer

382.50 ± 45.57

519.16 ± 52.13

0.001*

Inner nuclear layer

107.33 ± 33.33

142.5 ± 33.92

0.047*

Ganglion cell layer

9.5 ± 2.66

12.1 ± 3.61

0.11

10 mg/0.1 mL

0.1 mL

Outer nuclear layer

410.00 ± 54.40

510.00 ± 65.11

0.044*

Inner nuclear layer

99.33 ± 16.30

111.66 ± 25.34

0.045*

Ganglion cell layer

8.16 ± 3.92

9.16 ± 3.97

0.067

Light Microscopy

P-value

20 mg/0.2 mL

0.2 mL

Outer nuclear layer

335.00 ± 66.08

402.50 ± 73.65

0.045*

Inner nuclear layer

78.00 ± 14.35

88.00 ± 12.98

0.048*

Ganglion cell layer

6.50 ± 1.29

7.00 ± 1.63

0.2

Comparison between Golimumab and BSS groups was made with Student’s t-test. (P
≤ 0.05)

In the increasing doses and/or volumes of golimumab,
the percentage of TUNEL-positive cells was significantly
different in the ONL (P = 0.014), while there was no
significant difference in the INL and GCL (P = 0.337 and P
= 0.490, respectively). To investigate which groups created
the difference, the Mann–Whitney U test was executed.
There was a significant difference in the percentage of
TUNEL positive cells only between group I and group III
(P = 0.020); however, there was no significant difference
between group I and group II (P = 0.087); and group II and
group III (P = 1.00).
To analyze the volume effect on retinal layers, increasing
BSS injection volumes (0.05 mL, 0.1 mL, and 0.2 mL) were
performed. There was no significant difference in the
ONL, INL, and GCL staining percentages (P = 0.063, P
= 0.106, and P = 0.491, respectively). This was evidence
of apoptosis being independent of injected volume; thus,
the chemical effect of golimumab was the only reason for
apoptosis in this study.
TUNEL staining photographs of the rabbits’ study and
control eyes are shown in Figure 1.
3.1.2.2. Caspase-3 staining
Since caspase-3 activation is the most important indicator
of the irreversible point in programmed cell death,
cytoplasmic caspase expression was shown by using
antibodies developed against it. Caspase-3 staining was
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observed in the cytoplasm of photoreceptor cells (PR),
bipolar cells, and ganglion cells.
In the immunohistochemical examination, while
caspase-3 staining in the ONL and INL was significantly
higher in all three golimumab injected groups compared
to the BSS groups, there was no statistically significant
difference in the GCL. Caspase-3 staining percentages of
the cells in different retinal layers are shown in Table 2.
In the increasing doses and/or volumes of golimumab,
the percentage of caspase-positive cells was not significantly
different between the three retinal layers (P = 0.555, P
= 0.092, and P = 0.877, respectively). As for the volume
effect on apoptosis, there was no significant difference in
caspase positive cell percentages of the ONL, INL, and
GCL at increasing BSS volumes (P = 0.155, P = 0.236, and
P = 0.955, respectively). Caspase-3 staining photographs
of the rabbits’ study and control eyes are demonstrated in
Figure 2.
3.2. Electron microscopy
Mitochondrial crystalysis in the internal segment (Figures
3a and 3b) and destruction of disc structures of the external
segment (Figures 3c and 3d) of photoreceptors were
observed in both the drug and control groups. The most
prominent ultrastructural change observed in the retina
of the golimumab group was karyorrhexis in the nucleus
(Figure 3e) and myelin figures in the inner segments
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Table 2. Percentage of TUNEL-positive and caspase-3–positive cells at three different layers
of study and control groups.
Immunohistochemistry

Golimumab

BSS

P-value

TUNEL
5 mg/0.05 mL (n=6)

0.05 mL (n=6)

Outer nuclear layer

72.18 ± 1.66

68.77 ± 1.71

0.061

Inner nuclear layer

72.92 ± 1.39

55.72 ± 3.66

0.018*

Ganglion cell layer

100 (75–100)

100 (66–100)

0.937

10 mg/0.1 mL (n=6)

0.1 mL (n=6)

Outer nuclear layer

85.50 (72–88)

69.79 (57–78)

0.009*

Inner nuclear layer

75.62 ± 1.84

66.09 ± 2.91

0.020*

Ganglion cell layer

100 (66–100)

100 (60–100)

1

20 mg/0.2 mL (n=4)

0.2 mL (n=4)

Outer nuclear layer

87.22 (83–88)

72.77 (69–73)

0.029*

Inner nuclear layer

73.77 (63–77)

60.87 (47–66)

0.029*

Ganglion cell layer

100 (66–100)

100 (60–100)

1

5 mg/0.05 mL (n=6)

0.05 mL (n=6)

Outer nuclear layer

56.58 ± 1.54

48.00 (13–61)

0.048*

Inner nuclear layer

60.15 ± 4.44

42.36 (11–54)

0.015*

Ganglion cell layer

76.66 ± 8.33

63.54 (0–50)

0.064

10 mg/0.1 mL (n=6)

0.1 mL (n=6)

Outer nuclear layer

54.64 ± 3.16

44.27 (41–49)

0.041*

Inner nuclear layer

59.51 ± 3.55

48.77 ± 2.90

0.041*

Ganglion cell layer

58.33 ± 20.00

23.33 ±10.54

0.163

20 mg/0.2 mL (n=4)

0.2 mL (n=4)

Outer nuclear layer

52.89 (49–61)

38.49 (22–54)

0.048*

Inner nuclear layer

50.28 (44–52)

33.92 (28–55)

0.041*

Ganglion cell layer

66.66 (0–100)

25 (0–50)

0.198

All numerical values are expressed as Mean ± (Standard Deviation) for groups with normal
distribution, and Median (lowest–highest) for groups with nonnormal distribution. To
compare golimumab and BSS groups, Student’s t-test was used for groups with normal
distribution and Mann–Whitney U test was used for nonnormal distribution groups. (P ≤
0.05)

(Figure 3f) of the photoreceptor cells. Other layers of the
retina were evaluated as normal in all study groups. Figure
3 depicts EM photos of the rabbits’ study and control eyes.
4. Discussion
In the literature, several studies have evaluated the
retinal toxicity of anti-TNF drugs which were used offlabel [22,25–30]. Immunohistochemical analysis was
performed in only two studies to investigate the amount
of drug presence in the retina. Our study, unlike others,
evaluated apoptosis immunohistochemically and
investigated both quantitative and qualitative information

about retinal layers with light microscopic examination.
Functional evaluation with electroretinography (ERG)
could not be performed due to the lack of equipment. The
aforementioned studies are summarized in Table 3.
In our study, golimumab-injected eyes showed a
decreased number of cells in the ONL and INL in H&E
staining. To test if the decrease in cell number was due to
apoptotic cell death, we performed TUNEL and caspase-3
staining methods together to increase sensitivity and
specificity.
The TUNEL method, which is the standard technique
for demonstrating apoptosis, shows 3’-hydroxy groups,
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Figure 1. Examples from the study and control eyes of each group for TUNEL immunostaining. TUNEL-positive cells were
identified with red arrows.

i.e. DNA degradation products [31]. Necrosis, autolysis
and DNA chain fractures to be repaired later can also
be stained as TUNEL positive [32]. In contrast, if larger
destruction fragments are formed instead of nucleosomal
fragments by apoptosis, the number of apoptotic cells
detected by TUNEL will be accidentally low [33]
Caspase-3 staining is a cytoplasmic apoptosis marker
and is highly specific. It functions in the early stages of
apoptosis, whereas DNA degradation products stained
with TUNEL are late findings of this process. [34].
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However, apoptosis may occur without caspase activation
or by other caspases other than caspase-3, which reduces
the sensitivity of caspase-3 staining [35]. In accordance
with the literature, the percentage of TUNEL staining in
our study was higher than the percentage of caspase-3
staining in all groups [36].
In all study groups, the percentage of cells stained
positive in the INL was significantly higher than the BSS
group in both staining methods. While the percentage
of TUNEL positive cells in the ONL was not different

DURMAZ ENGİN et al. / Turk J Med Sci

Figure 2. Examples from the study and control eyes of each group for caspase-3 immunostaining. Caspase-3–positive cells
were identified with red arrows.

from the control in group I, increased TUNEL positivity
was observed in groups II and III compared to controls.
In caspase-3 staining, the percentage of positive-stained
cells in all three doses was significantly higher than in the
control group. We think that the difference in the ONL is
because the cells in this layer might still be in early stages
of apoptosis, so they were stained with caspase-3 but not
with TUNEL.
Several studies in the literature have evaluated
the apoptotic effect of anti-TNF drugs by
immunohistochemistry. Paula et al. compared the

apoptotic effect of IVT adalimumab, sham injection,
and no injection to the rabbits’ eyes and found that the
caspase gene expression was similar between three groups
[37]. Ueda et al. found that infliximab and adalimumab
increased the amount of active caspase-3 compared
to golimumab, thus leading to more apoptotic DNA
fragmentation [38]
There was no significant difference in the percentage
of TUNEL and caspase-3 positive cells compared to the
control group in the golimumab group’s GCL. There are a
limited number of studies that investigate drug toxicity on
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Figure 3: a-b. Mitochondrial crystalysis (black arrow) in the photoreceptor inner segment. TEM, Golimumab X31.300, BSS X26.230
magnification c-d. Disruption of outer segments of photoreceptors (white arrow) TEM, Golimumab X17.130, BSS X24.140 magnification
e.Photoreceptor cell nucleus, more translucent than surrounding cells, and karyorrhexis (black dashed arrow) f. Myelin figure (white
dashed arrow) in the photoreceptor inner segment.

1118

Infliximab

Etanercept

Etanercept

Giansanti et al.
(2008) 25

Kivilcim et al.
(2007) 22

Fauser et al.
(2004) 27

Pigmented
rabbits

New Zealand
albino rabbit

New Zealand
albino rabbit

Adalimumab

New Zealand
albino rabbit

New Zealand
albino rabbit

Adalimumab

Manzano et al.
(2011) 30

Marmosets

Manzano et al.
(2008) 26

Infliximab

Melo et al.
(2012) 29

Not
mentioned

20

12

12

28

30

10

16

New Zealand
albino rabbit

New Zealand
albino rabbit

Golimumab

Our study

Number of
animal/eyes

Type of
Animal

Theodossiadis et
Infliximab
al. (2009) 28

Drug

Study

Light microscopy

No retinal abnormality in 1 mg
and 1.7 mg; significant edema
of the nerve fibers in two of
N/A
three eyes injected with 3.3 mg
infliximab

100 mcg/0.1 mL

No retinal abnormality in drug Presence of drug with
and control groups
IHC

125 mcg, 250 mcg,
500 mcg,
No retinal abnormality in drug
N/A
1 mg and 2.5 mg in and control groups
0.1 mL

L1, 1.7 and 3.3 mg
in 0.1 mL

0.25, 0.50 or
1 mg in 0.1 mL

N/A

Normal

Normal

No difference
compared to control

Normal in BSS, 0.25
and 0.50 mg; greater
N/A
than 30% reduction in
a and b wave in 1 mg

Normal in BSS, 0.25 and
0.50 mg of adalimumab;
inflammatory cell
infiltration in two of three
eyes in 1.0 mg group

N/A

N/A

N/A

N/A

Normal in saline, 1
and 2 mg; dosedependent reductions
in b-wave amplitude
in higher doses

1, 2, 5, 8, 10 or
20 mg in 0.1 mL

Normal in saline, 1 and 2 mg;
edema of ganglion
cells, nerve fibers layer and the N/A
inner plexiform layer in higher
doses

Normal up to 5 mg,
inconclusive in
10 mg due to
technical failure

Normal up to 5
mg, decrease in the
photopic-wave in the
10 mg group

Normal -clinically no
relevant- in drug and
control groups

No retinal abnormality in drug
N/A
and control groups

No retinal abnormality
in drug and control
groups

N/A

0.5, 1.0, 2.5, 5
and 10 mg in
0.1 mL

Myelin figures in
the inner segments
and karyorrhexis in
the nucleus of the
photoreceptor cells

Higher percentage of
TUNEL and Caspase
staining in 10 and
20 mg groups

No retinal abnormality in drug Presence of drug with
and control groups
IHC

Electron Microscopy

Immunohistochemistry ERG

100 or 400 mcg in
5 mcl

5 mg / 0.05 mL, 10
Decreased cell count in ONL
mg / 0.1 mL or 20
and INL; no difference in GCL
mg/0.2 mL

Dose

Table 3. Studies evaluating the retinal toxicity of anti-TNF drugs in the literature.
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ganglion cells. In the in vitro rat ganglion cell culture model,
Tezel et al. found that a caspase-independent pathway in
ganglion cells was speculated [39]. In the experimental retinal
degeneration model, Martínez-Fernández et al. suggested that
TNF-α induces cell death by the caspase-independent pathway
in the ONL and GCL and the caspase-dependent pathway in
the INL [40].
In our study, the difference in the percentage of caspase-3
positive cells in the GCL compared to the control group might
suggest that caspase-independent mechanisms are effective
in the process. Contrary to our findings, however, TUNEL
staining percentages should be different between the two
groups in this case. Although the ganglion cell count in the
study group decreased compared to the control group, the
difference was not significant. This may be explained by the
neuroprotective effect of TNF-α antagonism shown in the
studies mentioned, but also may be because of ganglion cell
counts being less than the cells in the other layers analyzed
(INL and ONL) in normal retina.
In the increasing doses of golimumab, the only significant
difference in apoptosis was found in 20 mg/0.2 mL group
compared to 5 mg/0.05 mL group with TUNEL staining.
Otherwise, no significant decrease in cell count or increase
in the apoptotic cell percentage with increasing golimumab
dose in H&E, TUNEL, and caspase-3 staining were seen. This
suggests that the toxicity of IVT golimumab may not be dosedependent for 5 mg, 10 mg, and 20 mg. However, we believe
that this finding should be supported by further studies with
larger numbers of groups where the drug is injected in a larger
dose range.
In this study, various retinal cells of rabbit eyes injected
with golimumab and BSS were evaluated with TEM. While
myelin figures and karyorrhexis—a sign of cell damage—were
observed in the drug group, increased intracellular space
and decreased cell numbers in the INL and ONL were also
prominent. Melo et al. observed that all retinal layers are normal
in marmoset eyes after IVT 100 mg and 400 mg infliximab or
BSS injections [29]. Inan et al. found mitochondrial swelling
and disruption in the crystalline structure of PR internal
segments in bevacizumab injected eyes [41].
The excipients of our injected drug include sorbitol,
histidine,
histidine
hydrochloride
monohydrate,

polysorbate 80, and water for injections. Histidine
and histidine hydrochloride monohydrate are already
tested for IVT route and approved for human diseases
as an anti-VEGF drug [42]. Damico et al. showed that
IVT injection of polysorbate 80 in the concentration
for IVT drug preparations did not cause any functional
alterations of rabbit retinas [43].
In human eye, vitreous humor is approximately 4 mL,
while volume of the rabbit vitreous is approximately 1.5
mL. In rabbits, the retina is less vascular and the lens is
larger. These factors may cause the pharmacokinetics
of drugs to be different from human eyes. Comparative
studies in the literature suggest that rabbit eyes are
useful and effective animal models for studying IVT
pharmacokinetics (clearance, distribution volume, and
half-life), but since the anti-TNF drug we administered
is targeting human TNF-α, its affinity to rabbit TNF-α
may vary [44–47]. Although this situation is not seen as
a significant confounding factor in our study evaluating
drug toxicity, it should be taken into consideration in
future studies.
Relatively short study duration, limited administered
dose range and the lack of functional tests (ERG, optical
coherence tomography, etc.) are the main limitations of
the present study.
To conclude, in this study, we observed that
golimumab caused apoptosis in both photoreceptors
and bipolar cells of the rabbit retina. Our study is first
to evaluate the retinal toxicity of a novel anti-TNF drug,
golimumab, in an animal model by light microscopy,
immunohistochemistry, and electron microscopy.
Thus, it pioneers future studies of its IVT use in human
diseases.
Considering that each intravitreal injection carries
the risk of ocular infection namely endophthalmitis; it is
advantageous that golimumab, which has a longer halflife and a higher potency, can be used at longer intervals
in inflammatory diseases of the eye.
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